Stockbiotech stocks
Oruka Stock Jumps as Its Psoriasis Drug Clears Skin Completely in 61% of Patients
2026-10-26
Oruka Stock Jumps as Its Psoriasis Drug Clears Skin Completely in 61% of Patients Oruka Therapeutics (Nasdaq: ORKA) surged in double digits on Monday, October 26, 2026, after its experimental psori...
Xencor Stock Catapults 25% to a Near Four-Year High After 'Unprecedented' Kidney Cancer Data
2026-10-26
Xencor Stock Jumped More Than 25% on Monday — Here Is the Short Answer Xencor (NASDAQ: XNCR) stock catapulted more than 25% on Monday, October 26, 2026, briefly hitting its highest level since Febr...
MacroGenics Stock Crashes 38% on 'Positive' Trial Data — Why MGNX Sold Off Anyway
2026-10-24
The Short Answer MacroGenics stock crashed 38.02% on Friday, October 23, 2026 — on the same day the company announced what it called "positive" Phase 1 trial data. MacroGenics (NASDAQ: MGNX) closed...
Aardvark Stock Crashes 65% to a Record Low: The Trial Data That Erased a Rally in Hours
2026-10-23
Aardvark stock crashed 64.8% in one day — here is what happened Aardvark Therapeutics (NASDAQ: AARD) closed at $1.39 on Friday, October 23, 2026, down 64.8% in a single session and at a new 52-week...
Bolt Biotherapeutics Stock Soars 49% in One Day: Inside the $120 Million Prana Reverse Merger
2026-10-23
Bolt Biotherapeutics stock closed up about 49% on Friday, October 23, 2026, after the company announced a sign-and-close reverse merger to acquire Prana Therapies alongside a $120 million private p...
Tango Therapeutics Stock Jumps 21% Premarket After 82% Pancreatic Cancer Response Data — Phase 3 Is Next
2026-10-23
Tango Therapeutics (NASDAQ: TNGX) jumped about 21% in premarket trading on Friday, October 23, 2026, after the company reported an 82% objective response rate for its vopimetostat plus daraxonrasib...
Aardvark Therapeutics Stock Surges 24% Premarket After FDA Lifts Clinical Hold on ARD-101
2026-10-23
The Short Answer Aardvark Therapeutics (Nasdaq: AARD) jumped about 24% in premarket trading on Friday, October 23, 2026, after the U.S. Food and Drug Administration lifted the clinical hold on ARD-...
Biohaven Stock Surges 37%: FDA Gives Vyglxia a Second Chance After Last Year's Rejection
2026-10-22
Biohaven (NYSE: BHVN) stock surged as much as 39% in premarket trading on Thursday, October 22, 2026, after the U.S. Food and Drug Administration accepted the company's resubmitted application for...